Latest research on Fluticasone

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis.

Fluticasone dosage

Traditionally, a high dose of ICS (eg, Fluticasone dipropionate 500 µg bid) is prescribed; however, there is little high-quality information available on the dose−response relationship. [source, 2016]
A study of once-daily Fluticasone furoate, at a dosage of 50−100 µg daily in addition to vilanterol, demonstrated a progressive treatment benefit, with no apparent benefit above this dose. [source, 2016]
Three of these studies (beclomethasone [23, 30] & Fluticasone [27]) that reported improved outcomes with ICS therapy had prescribed these higher doses [23, 24, 27, 30]. [source, 2016]
In regard to lower (<1000 μg/day) doses, one study (Budesonide [22]) reported improved outcomes at a dose of 800 μg/day, whereas two studies (beclomethasone [34] & Fluticasone [26]) report no benefit of ICS therapy with doses of 17 to 250 μg [26, 34]. [source, 2016]
In the Netherlands, the prevalence of Beclometasone prescribing during pregnancy was almost double the prevalence observed before and after pregnancy, with the increase coinciding with a reduction in the prescribing of Fluticasone and other ICS in a fixed-dose combination with a LABA. [source, 2016]
He continued to have intermittent odynophagia and oral ulcers despite high-dose Prednisone, swallowed Fluticasone, aggressive acid suppression, and certolizumab pegol. [source, 2016]
At HV1, baseline surveys were administered and a Doser- TM [28,29] device was attached to the controller medication metered dose inhaler to measure adherence rates, or the dose-counter number was recorded on controller-delivery devices using counters (such as Fluticasone diskus delivery systems). [source, 2015]
COPD treatment will consist of Salbutamol 100 µg/puff at a dose of two puffs three or four times daily, Ipratropium 20 µg/puff at a dose of two puffs two to four times daily, or Salbutamol and Ipratropium, if symptoms persist, for more than 2 weeks on individual regimen in mild cases; Salmeterol 250 µg/puff and Fluticasone 25 µg/puff at a dose of two puffs two times daily up to a maximum of four puffs twice daily in moderate-to-severe cases; if symptoms are not adequately reduced in 2 weeks, long-acting muscarine antagonist, for example, tiotropium 18 µg capsule, would be added to the regimen once daily, or sustained release of oral Theophylline 200 mg tablet would be administered twice daily. [source, 2015]
Where doses were recorded (beclometasone=28, or Fluticasone n=79), the prevalence of SST failure was highest in those patients taking the largest doses (Fig. 1C and D). [source, 2015]
The 30-min serum Cortisol levels were significantly lower in patients on the highest doses of both Beclometasone and Fluticasone in comparison with those patients on lower doses (Fig. 1E and F). [source, 2015]